Sartorius expands activities in South Korea and France – .

Sartorius expands activities in South Korea and France – .

The new investments will also create up to 1,250 jobs in the two countries.

Production of cell culture media in South Korea

In South Korea, Satorius will invest around 270 million euros ($ 300 million) by the end of 2024.

At the Songdo Biopharmaceutical Center in Incheon, the company will start production of cell culture media and assemble sterile systems for efficient and flexible manufacturing of biopharmaceuticals, as well as other operations. The investment will serve both South Korean and wider Asian markets.

The company’s site will cover some 25,000 square meters (270,000 square feet) and include an application center with laboratories as well as several buildings for manufacturing and logistics.

Sartorius’ existing activities in South Korea for service as well as marketing and sales will be transferred to the new site, which provides space for further extensions. Construction work on the site is expected to begin in the coming year and production operations are expected to start by the end of 2024.

Sartorius currently employs 180 people in South Korea, but will employ 750 more as part of the investment.

Sartorius Chairman and CEO Joachim Kreuzburg said: “The development of the biopharmaceutical industry in Asia and, in particular, South Korea, has entered a new phase characterized by a high rate of innovation and investment on the part of our customers.

“With our significant investments in Songdo, we will increase our capacity, bring production operations closer to our customers in the region, and dramatically increase our speed of delivery. “


Please enter your comment!
Please enter your name here